Hiroshima-based Phoenix Bio Establishes NYC Office
This article was originally published in PharmAsia News
Executive Summary
Hiroshima-based bioventure Phoenix Bio provides proprietary PXB-mice, chimeric mice with humanized livers, for new drug research and development. In recent years, the company has seen increasing orders for the mice from drug makers in the U.S. and Europe. Phoenix Bio estimates sales will triple from 2008 to ¥2 billion by 2010. Aiming to establish a manufacturing and testing presence in the U.S., the company is opening a New York City office, which will be staffed with four to five employees and start operation in July. (Click here for more - Japanese language